The week in pharma: action, reaction and insight – week to April 19, 2024

21 April 2024

By Barbara Obstoj-Cardwell. Editor

Research news featured heavily last week, first with US rare seizures drug developer Marinus Pharmaceuticals presenting disappointing Phase III results for its intravenous (IV) ganaxolone, causing an 80% capitalization hit. Amgen released positive Phase IIa data on its Tezspire in chronic obstructive pulmonary disease (COPD). In a bid to further expand indications for its tirzepatide, Eli Lilly released promising Phase III data for the drug in the treatment of sleep apnea. Also, Vertex Pharmaceuticals updated on its non-opioid pain candidate suzetrigine (VX-548).

Negative RAISE a huge disappointment for Marinus

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK